Zentri 2g (Ceftriaxone Sodium Hydrate)

Adult administration

Adults and children over 12 years: Administer 1–2 g (activity) of ceftriaxone by intravenous or intramuscular injection once a day. In cases of infections caused by organisms showing severe disease or moderate susceptibility, the dose may be increased up to 4 g (activity) once a day. Elderly patients: No need to change the adult dosage regimen. For the treatment of gonorrhea, a single intramuscular injection of 250 mg (activity) is recommended. For pre- and post-operative infections

Child administration

Neonates (up to 14 days old): Administer 20–50 mg per kg (activity) once a day, not exceeding 50 mg per kg (activity). Infants and children (from 15 days to 12 years): Do not have

This medication should not be mixed or administered together with solutions containing calcium or other drugs. Especially in neonates, there is a risk of precipitation when calcium is mixed with this drug, so it should not be administered. It should not be used in patients with a history of allergies to this drug or to cephalosporins and penicillin antibiotics, as well as in premature infants or certain neonates. Additionally, this formulation containing lidocaine should not be administered intravenously. Patients with a past history of drug allergies or those with allergic constitution, and patients with severe renal impairment should use this drug with caution and dosage adjustments or administration interval adjustments may be necessary. During the use of this medication, various adverse reactions such as eosinophilia, blood cell reduction, diarrhea, rash, liver dysfunction, etc. may occur, so patients should immediately consult a doctor if symptoms appear. Moreover, serious allergic reactions or severe side effects such as pseudomembranous colitis, interstitial pneumonia, and renal failure can occur rarely, so the patient's condition should be closely monitored during administration. To prevent the development of resistant bacteria, this medication should be administered only for the necessary duration after susceptibility testing, and it is advisable to check for allergies through skin reaction tests or patient inquiries before administration. Regular blood tests for liver and kidney function and blood tests should be performed during treatment, especially for doses exceeding 1g per day, because deposits may form in the gallbladder, requiring due caution. In case of overdose, as there is no specific antidote, treatment according to symptoms should be provided, and this medication may cause dizziness, affecting driving or operating machinery, so care should be taken. Women who are pregnant or may become pregnant, and nursing mothers should use this medication cautiously as its safety is not established, and it should not be administered to neonates or premature infants due to the risk of bilirubin encephalopathy. There may be drug interactions with this medication, particularly caution is required when combined with calcium-containing solutions, aminoglycoside antibiotics, vitamin K antagonists, etc. Lastly, the prepared solution should be used as soon as possible, and storage should comply with the specified time and temperature.

Serious side effects

Urticaria, swelling, severe allergic reactions, severe swelling (edema), anaphylaxis and anaphylactoid reactions, severe skin reactions (severe cutaneous adverse reactions, erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS syndrome), respiratory distress, respiratory issues (asthma attack, respiratory abnormalities accompanied by fever), liver issues (jaundice, increased liver enzymes, elevated bilirubin, kernicterus), severe neurological symptoms (encephalopathy, seizures

Mild side effects

• Eosinophilia
• leukopenia
• thrombocytopenia
• diarrhea
• rash
• increased liver enzymes
• headache
• dizziness
• bronchospasm
• loose stools

This medication should be stored in a sealed container to avoid air exposure, preferably at room temperature between 1 and 30 degrees Celsius. Storing it this way ensures the safety of the drug's efficacy.

Appearance

A colorless, transparent vial filled with white to pale yellow crystalline powder

Package unit

1 vial, 10 vials